Adaptive immune system via antigen presentation and cytokine induction Overview
The adaptive immune system via antigen presentation and cytokine induction represents a fundamental biological process rather than a single molecular target. It involves the recognition of specific non-self antigens by T and B lymphocytes, a process mediated by professional antigen-presenting cells (APCs) that display peptide fragments on Major Histocompatibility Complex (MHC) molecules (Janeway et al., Immunobiology, 2001). Upon recognition, a cascade of signaling events leads to the induction of cytokines, which act as chemical messengers to coordinate the immune response, promote cell proliferation, and direct effector functions (NCBI, The Immune System, 2023). This system is critical for pathogen clearance and immunological memory, but its dysfunction is a primary driver in many pathologies, including autoimmune diseases where the system attacks host tissues and cancer where the system is often suppressed (Nature Reviews Immunology, 2020). Pharmacological intervention typically focuses on specific nodes within this process, such as blocking pro-inflammatory cytokines like TNF-alpha or modulating T-cell checkpoints like PD-1 to restore or suppress immune activity (PubMed, PMC7358229).
Mechanism of Action
Modulation of T-cell activation, inhibition of cytokine signaling cascades, or blockade of antigen presentation pathways to either suppress or enhance the immune response.
Biological Functions
Disease Associations
Safety Considerations
- Cytokine release syndrome (CRS)
- Increased susceptibility to opportunistic infections
- Autoimmune-related adverse events (irAEs)
- Immunosuppression
- Anaphylaxis
Interacting Drugs
Associated Biomarkers
| Biomarker |
|---|
| MHC class II expression |
| Interferon-gamma levels |
| CD4+/CD8+ T-cell ratios |
| Interleukin-2 (IL-2) concentration |
| T-cell receptor (TCR) repertoire diversity |
Gosset